-
381
Development and Validation of Patient Information Leaflet for Schizophrenia
Published 2025-01-01“…Methods: The PIL contents were generated from various sources of literature and discussion with several experts in the fields of psychiatry, dietetics, and pharmacy, followed by validation using the content validation index (CVI) method. …”
Get full text
Article -
382
Specialized contact sites regulate the fusion of chlamydial inclusion membranes
Published 2024-10-01Get full text
Article -
383
Implementation of Moodle, an open-source solution for Team Based Learning
Published 2024-12-01“…Two classes of professional pharmacy students were surveyed to capture perceptions of this novel use of the Moodle system. …”
Get full text
Article -
384
A systematic review of proaporphine alkaloids and a pharmacological update
Published 2025-02-01Get full text
Article -
385
The Considerable Case Reports: Observed Taenia Saginata after Consuming Undercooked Beef
Published 2025-02-01“…Initially, by going to a pharmacy, he purchased pyrvinium pamoate suspension", and began treatment (In February 2022, and again in May 2022). …”
Get full text
Article -
386
A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in...
Published 2025-03-01“…Study staff and participants were blinded to treatment assignment, except for pharmacy staff preparing the study drug. The ratio of active:placebo randomization to each cohort was set at 3:1. …”
Get full text
Article -
387
-
388
-
389
-
390
-
391
-
392
Natural products against resistant bacterial infections: A systematic literature review
Published 2025-03-01Get full text
Article -
393
-
394
-
395
Genetic advancements in breast cancer treatment: a review
Published 2025-02-01Get full text
Article -
396
-
397
-
398
Effect of 3-hydrazinylquinoxaline-2-thiol hydrogel on skin wound healing process in diabetic rats
Published 2024-08-01Get full text
Article -
399
Retrospective Analysis of Healthcare Resource Use, Treatment Patterns, and Treatment-related Events in Patients with Huntington’s Disease–associated Chorea Initiated on Tetrabenazi...
Published 2018-01-01“…During the 6-month post-index period after HD diagnosis, HD patients incurred higher all-cause healthcare costs ($20 204) vs the 6-month pre-index period ($6057), driven by higher hospitalization and pharmacy costs. **Conclusions:** A small percentage of HD patients with chorea were treated with tetrabenazine and discontinuation rates were high among those receiving treatment, with a median time to discontinuation of 9 months.…”
Get full text
Article -
400